GLP-1

News

Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.

News

Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.

News

The FDA has asked manufacturers of GLP-1 drugs used for weight loss to remove warnings of suicidal thinking, but added warnings to flu shots.

News

People who use drugs like GLP-1 agonists to lose weight regain it more quickly than those who use a conventional approach of diet and exercise.

News

Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.

News

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.